IP Library Granted Patent US 9,511,091
Granted Patent B2
US 9,511,091 · App. 14/860,023 · Granted Dec 6, 2016

Rare earth metal compounds, methods of making, and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,091
App. No.
14/860,023
Granted
Dec 6, 2016
Kind
B2
Abstract

Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.

Claims (11)

1. A method of treating hyperphosphatemia in a mammal, wherein the method comprises administering an effective amount of a composition comprising a rare earth compound selected from the group consisting of crystalline anhydrous La 2 O 2 CO 3 , crystalline anhydrous La 2 CO 5 , crystalline LaCO 3 OH, or a combination thereof, wherein the rare earth compound has a BET specific surface area of at least about 10 m 2 /g or more and exhibits a phosphate binding of at least 40% of an initial phosphate content after 10 minutes at an initial pH of about 3, at an amount of the rare earth compound 3 times the stoichiometric amount needed to react completely with the phosphate, and wherein the rare earth compound is in the form of particles with a porous structure.

2. The method of claim 1 , wherein the particles comprise individual crystals.

3. The method of claim 2 , wherein the crystals are between about 20 nanometers and 10 microns in size.

4. The method according to claim 1 , wherein the composition is administered as an orally ingestible form.

5. The method according to claim 4 , wherein the orally ingestible form is selected from the group consisting of a liquid solution, a liquid suspension, a tablet, a capsule, and a gel gap.

6. The method of claim 1 , wherein the rare earth compound is crystalline LaCO 3 OH.

7. The method of claim 6 , wherein the crystalline LaCO 3 OH is anhydrous.

8. The method of claim 1 , wherein the rare earth compound has a BET specific surface area of about 20 m 2 /g or more.

9. The method of claim 1 , wherein the particles are between about 1 and 1000 microns in size.

10. The method of claim 1 , wherein the rare earth compound is crystalline anhydrous La 2 O 2 CO 3 .

11. The method of claim 1 , wherein the rare earth compound is crystalline anhydrous La 2 CO 5 .

Assignments (4)
QUITCLAIM PATENT ASSIGNMENT WITH AN EFFECTIVE DATE OF 9/20/2018 Recorded Jun 29, 2021
From: SPECTRUM PHARMACEUTICALS, INC.
To: UNICYCIVE THERAPEUTICS, INC.
Reel/Frame 056713/0060 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2021
From: MOERCK, RUDI E.; SPITLER, TIMOTHY MALCOME; SCHAUER, EDWARD A.; PROCHAZKA, JAN
To: ALTAIR NANOMATERIALS INC.
Reel/Frame 056690/0048 →
CHANGE OF NAME Recorded Jun 28, 2021
From: ALTAIR NANOMATERIALS INC.
To: ALTAIRNANO, INC.
Reel/Frame 056698/0511 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2016
From: ALTAIRNANO, INC.
To: SPECTRUM PHARMACEUTICALS, INC.
Reel/Frame 040019/0165 →